PATIENTS' PRIORITIES IN THE TREATMENT OF NEUROENDOCRINE TUMORS- AN ANALYTIC HIERARCHY PROCESS
Author(s)
Mühlbacher AC, Juhnke C, Kaczynski A
Hochschule Neubrandenburg, Neubrandenburg, Germany
OBJECTIVES: Neuroendocrine tumors (NET) are relatively rare, usually slow-growing malignant tumors. So far there is no data on the patient preferences/priorities regarding the therapy of NET. This empirical study aimed at the elicitation of patient priorities in the drug treatment of NET. METHODS: Qualitative patient interviews (N=9) were conducted. To elicit patient's perspective regarding various treatment aspects of NET a self-administered questionnaire using Analytic Hierarchy Process (AHP) was developed. The data collection was carried out using paper questionnaires supported by an item response system in a group discussion. To evaluate the patient-relevant outcomes, the eigenvector method was applied. RESULTS: N=24 patients, experts and relatives participated in the AHP survey. In the AHP all respondents had clear priorities for all considered attributes. The attribute "overall survival" was the most significant feature of a drug therapy for all respondents. As in the qualitative interviews, "efficacy attributes" dominated the side effects in the AHP as well. The evaluation of all participants thus showed the attributes "overall survival" (Wglobal: 0.418), "progression free survival" (Wglobal: 0.172) and "response to treatment" (Wglobal: 0.161) to be most relevant. "Occurrence of abdominal pain" (Wglobal: 0.051) was ranked last, with "tiredness/fatigue" and "risk of a hypoglycemia" (Wglobal: 0.034) on a shared seventh place. CONCLUSIONS: The results thus provide evidence about how much influence a treatment capacity has on therapeutic decision. Using the AHP major aspects of drug therapy from the perspective of those affected were captured, and positive and negative therapeutic properties could be related against each other. Based on the assessment of the patient's perspective further investigation must elicit patient preferences for NET drug therapy. In the context of a discrete choice experiment or another choice -based method of preference measurement, the results obtained here can be validated and the therapeutic features weighted according to their preferability.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PCN201
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes, Stated Preference & Patient Satisfaction
Disease
Oncology, Rare and Orphan Diseases